COSCIENS Biopharma Inc. (CSCI)

Price Chart

COSCIENS Biopharma Inc. (CSCI) stock price: $2.10 (+0.12, +5.85%)

Why Bull

• •Recent insider buying suggests confidence in the company's future, indicating that executives believe in its growth potential.
• •Community sentiment has shifted positively, with discussions highlighting the company's innovative projects and strong management team.
• •Positive media coverage has increased, focusing on CSCI's unique market position and strategic partnerships that enhance its competitive edge.
• •Recent product launches have garnered attention, showcasing the company's commitment to innovation and responsiveness to market needs.

Why Bear

• •Some analysts express concerns over the company's ability to scale operations effectively, which could hinder growth.
• •Community discussions reveal skepticism regarding CSCI's market strategy, with some members doubting its sustainability in a competitive landscape.
• •Recent regulatory challenges have emerged, raising questions about potential operational disruptions and compliance costs.
• •There is a notable decline in social media engagement around CSCI, suggesting waning interest or confidence among retail investors.

• COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
  Yahoo! Finance: CSCI News · Dec 1, 2025
• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  benzinga · Sep 3, 2025
• 12 Health Care Stocks Moving In Monday's After-Market Session
  benzinga · Aug 25, 2025
• 12 Health Care Stocks Moving In Friday's After-Market Session
  benzinga · Aug 22, 2025

Rationale

AI-generated technical analysis for CSCI including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for COSCIENS Biopharma Inc. (CSCI), choose a timeframe, and track your prediction accuracy.

Current price: $2.10

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 5/100

  Revenue growth data is currently unavailable for this company.

• Gross Margin 5/100

  Gross margin data is currently unavailable for this company.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates CSCI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Is CSCI a good stock to buy?

Whether CSCI is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the CSCI MoonshotScore?

The MoonshotScore for CSCI is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is CSCI data updated?

CSCI stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CSCI is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for CSCI?

Growth catalysts for COSCIENS Biopharma Inc. (CSCI) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes COSCIENS Biopharma Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are CSCI's main competitors?

COSCIENS Biopharma Inc. (CSCI) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CSCI has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about CSCI?

Wall Street analyst coverage for CSCI includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is CSCI's market cap?

Market capitalization (market cap) for CSCI is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CSCI's current market cap alongside enterprise value and other valuation metrics.

How has CSCI stock performed recently?

CSCI's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CSCI's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in CSCI?

Key risk categories for CSCI include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CSCI's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling CSCI?

Insider trading activity for CSCI tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is CSCI a good stock for beginners?

COSCIENS Biopharma Inc. (CSCI) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is CSCI for first-time investors?

Every stock carries risk, including COSCIENS Biopharma Inc. (CSCI). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CSCI.

CSCI vs S&P 500: which is better for new investors?

The S&P 500 (SPY) offers broad diversification across 500 large U.S. companies, making it a lower-risk starting point for new investors. COSCIENS Biopharma Inc. (CSCI) is a single stock with higher potential upside but also more concentrated risk. Most financial advisors suggest new investors start with index funds like the S&P 500 and gradually add individual stocks like CSCI as they gain experience. Compare CSCI's MoonshotScore and volatility to the broad market before deciding.

What should beginners know before buying CSCI?

Before buying COSCIENS Biopharma Inc. (CSCI), beginners should understand: (1) the company's business model and how it makes money (see the Company Overview on this page), (2) its financial health through revenue growth and gross margins (see MoonshotScore Breakdown), (3) what analysts are saying (check the Analyst Consensus tab), and (4) the key risks (see Risk Factors). Start with a small position you are comfortable losing entirely, and consider dollar-cost averaging instead of investing a lump sum.

How much money do I need to start investing in CSCI?

You can start investing in COSCIENS Biopharma Inc. (CSCI) with as little as $1 through fractional shares, which most modern brokers offer. There is no minimum investment required. However, financial experts typically recommend only investing money you will not need for at least 3-5 years. Before buying CSCI, make sure you have an emergency fund covering 3-6 months of expenses and no high-interest debt. Check the current CSCI share price at the top of this page.